Christoph Röllig, MD, Dresden University of Technology, Dresden, Germany, describes the breaking down of diagnostic and treatment algorithms to aid in the selection of front-line de novo acute myeloid leukemia (AML) therapy. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.
